These 59 studies focus on the use of CD4 (5 studies), CD5 (5 studies), CD7 (28 studies), CD30 (17 studies), CD37 (1 study), CD123 (1 study), CD147 (1 study), or TRBC1 (2 studies)-specific CARs to target a diverse range of T-cell malignancies, including T-ALL, PTCL, T cell lymphoblastic lymphoma (T-LBL), anaplastic large cell lymphoma (ALCL), adult T cell leukemia/lymphoma, angioimmunoblastic T cell lymphoma (AITL), enteropathy-associated T cell lymphoma, and extramedullary NK/T cell lymphoma. This evidence concerns the gene CD37 and mature T-cell and NK-cell non-Hodgkin lymphoma.